Medical Condition News

RSS

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

Low gut microbial diversity in infants' intestines can increase risk for asthma

Low gut microbial diversity in the intestines of infants can increase the risk for asthma development. These are the findings of the age 7 follow-up in a multi-year study led by researchers at Linköping University in Sweden.

7 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Synthetic cannabinoid molecule created for osteoarthritis

Chemical compounds synthesised in the laboratory, similar to those found in cannabis, could be developed as potential drugs to reduce the pain of osteoarthritis.

7 Jan 2014

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

Quality of life considerations are key when patients consider bariatric surgery

While weight loss surgery offers one of the best opportunities to improve health and reduce obesity related illnesses, the nearly 100,000 Americans who undergo bariatric surgery each year represent only a small fraction of people who are medically eligible for the procedure. Among those who have surgery, Caucasian Americans are twice as likely as African Americans to have weight loss surgery. On the surface, the data appear to signal racial disparity, but when researchers at Beth Israel Deaconess Medical Center dug deeper to ask why this variation exists, the answer was more complicated.

7 Jan 2014

Study: Long-term weight loss maintenance possible if individuals adhere to key health behaviors

Researchers from The Miriam Hospital have published one of the first studies of its kind to follow weight loss maintenance for individuals over a 10-year period. The results show that long-term weight loss maintenance is possible if individuals adhere to key health behaviors. The study is published in the January 2014 issue of the American Journal of Preventive Medicine.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Memorial Sloan-Kettering Cancer Center receives $90M in new financial support from Ludwig

Memorial Sloan-Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Announced today, the gift is among the largest publicly recorded gifts to cancer research made by a private organization, bringing the total funding to date for Ludwig Centers and endowed professorships at the six institutions to $900 million.

7 Jan 2014

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.

7 Jan 2014

ObamaCare can be a costly shift for people suffering with obstructive sleep apnea

Health insurance is a fast changing landscape in the United States with the implementation of ObamaCare, also known as The Affordable Health Care Act. Health insurance companies are doing something called cost shifting where the cost of care gets shifted onto the patients. For people who suffer with obstructive sleep apnea, this is can be a costly shift.

7 Jan 2014

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.

7 Jan 2014

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog, Eli Lilly) using its proprietary technology BioChaperone).

7 Jan 2014

Study suggests new target for drugs to treat head and neck tumors

The increased activation of a key oncogene in head and neck cancers could be the result of mutation and dysfunction of regulatory proteins that are supposed to keep the gene, which has the potential to cause cancer, in check, according to a new study led by researchers at the University of Pittsburgh School of Medicine.

7 Jan 2014

Second module of PMA application submitted to FDA for Sapheon's VenaSeal Sapheon Closure System

Sapheon Inc. announced today that it has submitted the second module of the pre-market approval application for the VenaSeal Sapheon Closure System to the U.S. Food and Drug Administration.

7 Jan 2014

New guidelines provide screening recommendations for people at higher risk of developing lung cancer

Alarmingly, more than 200,000 Americans will be diagnosed with lung cancer this year and nearly 160,000 people will die of the disease. In fact, according to the American Cancer Society, lung cancer takes more lives each year than colorectal, breast and prostate cancers combined.

7 Jan 2014

Study shows binge-eating disorder is associated with substantial lifelong impairments

Binge-eating disorder, designated in 2013 by the American Psychiatric Association as a diagnosis in its Diagnostic and Statistical Manual of Mental Disorders-V, is associated with substantial lifelong impairments comparable to those of bulimia nervosa, according to a recent World Health Organization study based on community epidemiological surveys conducted in 12 nations worldwide.

7 Jan 2014

Medical Condition News

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

Low gut microbial diversity in infants' intestines can increase risk for asthma

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Synthetic cannabinoid molecule created for osteoarthritis

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Quality of life considerations are key when patients consider bariatric surgery

Study: Long-term weight loss maintenance possible if individuals adhere to key health behaviors

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Memorial Sloan-Kettering Cancer Center receives $90M in new financial support from Ludwig

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

ObamaCare can be a costly shift for people suffering with obstructive sleep apnea

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

Study suggests new target for drugs to treat head and neck tumors

Second module of PMA application submitted to FDA for Sapheon's VenaSeal Sapheon Closure System

New guidelines provide screening recommendations for people at higher risk of developing lung cancer

Study shows binge-eating disorder is associated with substantial lifelong impairments

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News